New generation of
smarter medicines
Developing differentiated
cancer therapeutics
Senti Bio is a clinical-stage company developing a new generation of cell and gene therapies for patients living with incurable diseases. To achieve this, we are leveraging our synthetic biology platform to engineer Gene Circuits into new medicines with enhanced precision and control. These Gene Circuits are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target tissues and/or to be controllable even after administration. Our wholly-owned pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. Our Gene Circuits have been shown to work clinically and preclinically, and to work in both NK and T cells which allows us to select the right cell type for each indication. We have demonstrated the potential depth and breadth of Gene Circuits in other modalities and diseases outside of oncology preclinically, and continue to advance these capabilities through partnerships.
Engineering smarter
medicines by programming
cells with Gene Circuits
We are primarily focused on advancing cell therapy programs for oncology indications. Our lead product candidate, SENTI-202, is currently being evaluated in a global clinical trial for the treatment of acute myeloid leukemia (AML) and has demonstrated positive preliminary efficacy data.
“The field of synthetic biology has evolved rapidly over the past few decades. We believe that we are uniquely positioned to harness its potential to drive significant advances in medicine.”
Tim Lu, MD, PhD
Co-Founder and CEO, Senti Bio
